SEATTLE, Wash., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. `Neoleukin` (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced a corporate update and financial results for the third quarter ending September 30, 2019. `The past quarter has been transformational for Neoleukin across many fronts. We`ve acquired the capital for further development of our de novo protein technology, expanded our talented team, and focused on advancing NL-201 for clinical evaluation,` said Jonathan Drachman, M.D., Chief Executive Officer of Neoleukin. `Additionally, we look forward to presenting data in the...
|
